Inactive Instrument

News Bone Therapeutics SA Euronext Bruxelles

Equities

BOTHE

BE0974280126

End-of-day quote Euronext Bruxelles Other stock markets
-	-

11/04	Biosenic: launch of a debt restructuring plan	CF
12/03	Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BioSenic S.A. : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of Nivelles	27/05	GL
BioSenic provides First Quarter 2024 Business Update	24/05	GL
BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles	26/04	GL
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023	24/04	GL
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023	24/04	AQ
BioSenic S.A. : Transparency notifications received from François Rieger	18/04	GL
BioSenic provides further information on its restructuring plan	12/04	GL
BioSenic : summary bonds refinancing_20240411	12/04	PU
Biosenic: launch of a debt restructuring plan	11/04	CF
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles	11/04	GL
BioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles	11/04	AQ
BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress	20/03	GL
BioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease	12/03	GL
Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	12/03	CI
BioSenic Raises Capital to Fund US FDA Application for Oral Arsenic Trioxide	05/02	MT
BioSenic raises €500,000 in private placement of new shares with established new investors	02/02	GL
BioSenic S.A. announced that it has received ?0.5 million in funding from Société Boursier.com SA, Gestys Sprl, Friedland Gestion	02/02	CI
BioSenic provides support to forthcoming European conference on graft-versus-host disease	31/01	GL
BioSenic Unit Wins Canadian Patent for Therapeutic Platform	30/01	MT
BioSenic patent granted in Canada for broader protection of ATO therapeutic platform	30/01	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Bone Therapeutics SA Euronext Bruxelles

Equities

BOTHE

BE0974280126

Summary

Filters